A Real World Study About PMN

Launched by WEI CHEN · Mar 19, 2025

Keywords

ClinConnect Summary

This clinical trial is focused on finding the best way to treat a kidney condition called Primary Membranous Nephropathy (PMN). Researchers want to compare two treatment approaches: one that combines a medication called rituximab with hormones, and another that uses only rituximab. In addition to the main study, there is a separate real-world component where patients who don't qualify for the main trial can still be observed to see how the treatments work in a wider group of people.

To be eligible for participation, you must be at least 18 years old and have been diagnosed with PMN through a kidney biopsy. Also, if you've been treated with certain medications for your condition for at least three months but still have high levels of protein in your urine, you may qualify. If you join the study, you can expect to receive either of the treatment options being tested and be closely monitored by medical professionals. This trial is currently recruiting participants, and it’s open to both men and women.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1.Men and Women aged over 18 years; 2.Patients diagnosed as primary membranous nephropathy (PMN) by renal biopsy; 3.After treatment with ACE inhibitors or ARBs for at least 3 months, those who have an average 24-hour urine protein ≥ 3.5g twice a week.
• • -
• Exclusion Criteria:
• • 1. Patients with secondary membranous nephropathy (such as hepatitis B and C, systemic lupus erythematosus, drug therapy, malignant tumors and other secondary causes;
• • 2. Active infection, such as active hepatitis B or hepatitis C, tuberculosis (evidence of active tuberculosis infection within 1 year), or human immunodeficiency virus HIV infection (positive for anti-HIV antibodies), etc.
• • 3. A history of immunodeficiency, including other acquired or congenital immunodeficiency diseases, or organ transplantation.
• • -